Septerna (NASDAQ:SEPN) Insider Sells 2,178 Shares

Septerna, Inc. (NASDAQ:SEPN) insider Samira Shaikhly sold 2,178 shares of the company’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $35.18, for a total value of $76,622.04. Following the completion of the transaction, the insider directly owned 793 shares in the company, valued at $27,897.74. This represents a 73.31% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Samira Shaikhly also recently made the following trade(s):

• On Friday, June 12th, Samira Shaikhly sold 6,250 shares of Septerna stock. The stock was sold at an average price of $35.08, for a total value of $219,250.00.
• On Monday, June 1st, Samira Shaikhly sold 5,935 shares of Septerna stock. The stock was sold at an average price of $28.93, for a total value of $171,699.55.
• On Tuesday, May 26th, Samira Shaikhly sold 11,798 shares of Septerna stock. The stock was sold at an average price of $30.06, for a total value of $354,647.88.

Septerna Stock Down 3.6%

Shares of NASDAQ SEPN traded down $1.26 during mid-day trading on Tuesday, hitting $33.49. 747,642 shares of the company traded hands, compared to its average volume of 338,290. Septerna, Inc. has a 1 year low of $10.30 and a 1 year high of $37.99. The stock has a market capitalization of $1.51 billion, a price-to-earnings ratio of -41.35 and a beta of 2.39. The business has a 50 day moving average of $29.43 and a two-hundred day moving average of $27.43.

Septerna (NASDAQ:SEPN) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.23. The firm had revenue of $26.52 million for the quarter, compared to analysts’ expectations of $16.98 million. Septerna had a negative return on equity of 12.72% and a negative net margin of 49.88%. As a group, research analysts anticipate that Septerna, Inc. will post -1.57 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on SEPN shares. Wells Fargo & Company boosted their price target on shares of Septerna from $28.00 to $48.00 and gave the company an “overweight” rating in a report on Tuesday, March 3rd. JPMorgan Chase & Co. raised their price objective on shares of Septerna from $34.00 to $38.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 24th. Guggenheim began coverage on shares of Septerna in a research report on Thursday, June 11th. They set a “buy” rating and a $52.00 price objective on the stock. Wall Street Zen downgraded shares of Septerna from a “buy” rating to a “hold” rating in a research note on Saturday, March 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $45.78.

Hedge Funds Weigh In On Septerna

Institutional investors and hedge funds have recently bought and sold shares of the business. Goldman Sachs Group Inc. lifted its position in shares of Septerna by 86.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company’s stock worth $75,698,000 after purchasing an additional 1,260,409 shares in the last quarter. Vanguard Group Inc. increased its stake in Septerna by 7.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,518,757 shares of the company’s stock valued at $28,568,000 after buying an additional 104,394 shares during the period. Avoro Capital Advisors LLC increased its stake in Septerna by 8.1% in the 3rd quarter. Avoro Capital Advisors LLC now owns 1,337,500 shares of the company’s stock valued at $25,158,000 after buying an additional 100,000 shares during the period. ADAR1 Capital Management LLC lifted its position in Septerna by 38.9% in the 3rd quarter. ADAR1 Capital Management LLC now owns 1,176,491 shares of the company’s stock worth $22,130,000 after buying an additional 329,264 shares in the last quarter. Finally, Janus Henderson Group PLC purchased a new stake in Septerna in the 1st quarter worth approximately $21,334,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.